| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premature Birth | 13 | 2023 | 418 | 3.210 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2023 | 343 | 2.690 |
Why?
|
| Prenatal Care | 11 | 2023 | 361 | 1.840 |
Why?
|
| Glucocorticoids | 8 | 2024 | 400 | 1.680 |
Why?
|
| Pregnancy | 52 | 2024 | 7593 | 1.540 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2022 | 82 | 1.440 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2013 | 62 | 1.150 |
Why?
|
| Pregnancy Complications | 7 | 2011 | 553 | 1.130 |
Why?
|
| Gestational Age | 12 | 2024 | 1230 | 1.120 |
Why?
|
| Pre-Eclampsia | 4 | 2020 | 230 | 1.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2024 | 243 | 1.020 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 679 | 1.000 |
Why?
|
| Amniotic Fluid | 5 | 2016 | 154 | 0.960 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2013 | 1008 | 0.910 |
Why?
|
| Obstetric Labor, Premature | 6 | 2011 | 85 | 0.900 |
Why?
|
| Fetal Viability | 1 | 2024 | 30 | 0.880 |
Why?
|
| Perinatal Care | 1 | 2024 | 68 | 0.840 |
Why?
|
| Antithrombin III | 2 | 2013 | 28 | 0.770 |
Why?
|
| Thrombin | 2 | 2013 | 62 | 0.760 |
Why?
|
| Peptide Hydrolases | 2 | 2013 | 149 | 0.720 |
Why?
|
| Progesterone | 3 | 2009 | 635 | 0.680 |
Why?
|
| Female | 54 | 2025 | 71439 | 0.600 |
Why?
|
| Decision Making | 2 | 2024 | 701 | 0.600 |
Why?
|
| Edema | 3 | 2013 | 147 | 0.600 |
Why?
|
| Dexamethasone | 6 | 2013 | 281 | 0.580 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 548 | 0.580 |
Why?
|
| Progestins | 2 | 2009 | 51 | 0.580 |
Why?
|
| Infant, Newborn | 11 | 2024 | 8628 | 0.530 |
Why?
|
| Fetal Organ Maturity | 4 | 2011 | 14 | 0.510 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 3 | 2004 | 6 | 0.500 |
Why?
|
| Humans | 62 | 2025 | 133271 | 0.490 |
Why?
|
| Diseases in Twins | 2 | 2005 | 99 | 0.460 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2016 | 170 | 0.450 |
Why?
|
| Breech Presentation | 2 | 2006 | 20 | 0.450 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 116 | 0.450 |
Why?
|
| Cultural Diversity | 1 | 2015 | 71 | 0.440 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 52 | 0.440 |
Why?
|
| Cultural Competency | 1 | 2015 | 53 | 0.430 |
Why?
|
| Cervix Uteri | 4 | 2013 | 63 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1214 | 0.410 |
Why?
|
| Breast Diseases | 2 | 2004 | 38 | 0.410 |
Why?
|
| Foot Diseases | 1 | 2013 | 23 | 0.400 |
Why?
|
| Turner Syndrome | 1 | 2013 | 46 | 0.390 |
Why?
|
| Delivery, Obstetric | 3 | 2018 | 260 | 0.380 |
Why?
|
| Cerclage, Cervical | 2 | 2009 | 12 | 0.380 |
Why?
|
| Pregnancy Outcome | 9 | 2008 | 637 | 0.380 |
Why?
|
| Pregnancy, High-Risk | 2 | 2009 | 43 | 0.370 |
Why?
|
| Betamethasone | 5 | 2011 | 14 | 0.370 |
Why?
|
| Cervical Ripening | 2 | 2008 | 7 | 0.350 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 448 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 906 | 0.340 |
Why?
|
| Uterine Cervical Incompetence | 2 | 2006 | 6 | 0.310 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 658 | 0.300 |
Why?
|
| Fetal Growth Retardation | 1 | 2011 | 257 | 0.300 |
Why?
|
| Proteinuria | 3 | 2020 | 111 | 0.300 |
Why?
|
| Placenta | 2 | 2016 | 548 | 0.300 |
Why?
|
| Labor Onset | 1 | 2008 | 4 | 0.290 |
Why?
|
| HELLP Syndrome | 1 | 2007 | 17 | 0.270 |
Why?
|
| Down Syndrome | 1 | 2010 | 231 | 0.260 |
Why?
|
| Adult | 18 | 2017 | 31650 | 0.250 |
Why?
|
| Vaginosis, Bacterial | 1 | 2006 | 19 | 0.250 |
Why?
|
| Heart Ventricles | 1 | 2011 | 789 | 0.250 |
Why?
|
| Trial of Labor | 1 | 2006 | 23 | 0.250 |
Why?
|
| Thanatophoric Dysplasia | 1 | 2005 | 6 | 0.240 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2005 | 20 | 0.240 |
Why?
|
| Oocyte Donation | 1 | 2025 | 7 | 0.240 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 47 | 0.240 |
Why?
|
| Airway Obstruction | 1 | 2007 | 168 | 0.240 |
Why?
|
| Time Factors | 7 | 2016 | 6545 | 0.230 |
Why?
|
| Estrogen Antagonists | 1 | 2005 | 107 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 105 | 0.220 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2025 | 76 | 0.220 |
Why?
|
| Transient Tachypnea of the Newborn | 1 | 2024 | 2 | 0.220 |
Why?
|
| Environmental Pollutants | 1 | 2005 | 80 | 0.220 |
Why?
|
| NF-kappa B | 1 | 2007 | 477 | 0.220 |
Why?
|
| Community Health Planning | 1 | 2003 | 8 | 0.210 |
Why?
|
| Maternal Exposure | 1 | 2005 | 155 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2020 | 77 | 0.210 |
Why?
|
| Mammaplasty | 1 | 2004 | 54 | 0.210 |
Why?
|
| Uterine Rupture | 1 | 2003 | 18 | 0.200 |
Why?
|
| Urogenital Abnormalities | 1 | 2005 | 168 | 0.200 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2003 | 98 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2024 | 192 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 410 | 0.190 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 85 | 0.190 |
Why?
|
| Cesarean Section | 2 | 2018 | 402 | 0.190 |
Why?
|
| Diabetes, Gestational | 1 | 2003 | 115 | 0.180 |
Why?
|
| Biomarkers | 4 | 2020 | 3418 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2025 | 507 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2003 | 188 | 0.180 |
Why?
|
| Cocaine | 1 | 2003 | 208 | 0.180 |
Why?
|
| Tocolytic Agents | 2 | 2011 | 12 | 0.180 |
Why?
|
| Risk Factors | 6 | 2016 | 10956 | 0.170 |
Why?
|
| Cocaine-Related Disorders | 1 | 2003 | 204 | 0.170 |
Why?
|
| Pregnancy, Multiple | 1 | 2000 | 48 | 0.170 |
Why?
|
| Embryo Transfer | 1 | 2000 | 61 | 0.160 |
Why?
|
| Maternal Age | 2 | 2011 | 141 | 0.160 |
Why?
|
| Eclampsia | 1 | 2020 | 29 | 0.160 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 982 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2016 | 487 | 0.160 |
Why?
|
| Cholecystectomy | 1 | 2019 | 63 | 0.150 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 1887 | 0.150 |
Why?
|
| Fetal Diseases | 1 | 2003 | 461 | 0.150 |
Why?
|
| Fertilization in Vitro | 1 | 2000 | 162 | 0.150 |
Why?
|
| Meningocele | 1 | 2018 | 18 | 0.150 |
Why?
|
| Mass Screening | 2 | 2020 | 835 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2003 | 683 | 0.140 |
Why?
|
| Lung | 5 | 2011 | 1569 | 0.130 |
Why?
|
| Parents | 1 | 2024 | 1073 | 0.130 |
Why?
|
| Hypertension | 1 | 2005 | 1402 | 0.130 |
Why?
|
| Creatinine | 2 | 2008 | 418 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 135 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 96 | 0.120 |
Why?
|
| Postpartum Hemorrhage | 1 | 2017 | 108 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2001 | 858 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 142 | 0.120 |
Why?
|
| Complement C4a | 1 | 2015 | 4 | 0.120 |
Why?
|
| Complement Factor B | 1 | 2015 | 11 | 0.120 |
Why?
|
| Peptide Hormones | 1 | 2016 | 71 | 0.120 |
Why?
|
| Complement C5a | 1 | 2015 | 22 | 0.120 |
Why?
|
| Peer Review | 1 | 2015 | 41 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 123 | 0.120 |
Why?
|
| Meningomyelocele | 1 | 2018 | 255 | 0.110 |
Why?
|
| Amniocentesis | 2 | 2012 | 77 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1156 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2009 | 999 | 0.110 |
Why?
|
| Brain | 2 | 2024 | 3223 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2016 | 180 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 748 | 0.110 |
Why?
|
| Publishing | 1 | 2015 | 115 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2013 | 640 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2007 | 4915 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Hypoxia, Brain | 1 | 2013 | 35 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 139 | 0.100 |
Why?
|
| Syndrome | 2 | 2007 | 1174 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1340 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2018 | 1254 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2011 | 19 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3171 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 744 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 124 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3411 | 0.090 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2009 | 9 | 0.080 |
Why?
|
| Chimerism | 1 | 2010 | 29 | 0.080 |
Why?
|
| Parity | 1 | 2010 | 87 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2011 | 242 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 772 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 384 | 0.080 |
Why?
|
| Fetal Mortality | 1 | 2008 | 7 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2011 | 208 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 3105 | 0.070 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2008 | 33 | 0.070 |
Why?
|
| Procollagen | 1 | 2008 | 17 | 0.070 |
Why?
|
| Uremia | 1 | 2008 | 35 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2004 | 3794 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 43 | 0.070 |
Why?
|
| Glomerulonephritis | 1 | 2008 | 75 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2008 | 47 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2010 | 133 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2008 | 124 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2010 | 153 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 59 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2008 | 87 | 0.070 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2007 | 19 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 113 | 0.070 |
Why?
|
| Oxytocin | 1 | 2008 | 74 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 1185 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 823 | 0.060 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 57 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2011 | 633 | 0.060 |
Why?
|
| Version, Fetal | 1 | 2006 | 6 | 0.060 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 167 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 306 | 0.060 |
Why?
|
| Trachea | 1 | 2007 | 212 | 0.060 |
Why?
|
| Potassium Chloride | 1 | 2005 | 55 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2007 | 229 | 0.060 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 128 | 0.060 |
Why?
|
| Cryptorchidism | 1 | 2005 | 37 | 0.060 |
Why?
|
| Injections | 1 | 2005 | 156 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 839 | 0.060 |
Why?
|
| Fetus | 1 | 2008 | 601 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 17556 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 863 | 0.060 |
Why?
|
| Anemia | 1 | 2008 | 349 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2011 | 13102 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 180 | 0.060 |
Why?
|
| Emergencies | 1 | 2005 | 187 | 0.050 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 6582 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2008 | 828 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 1582 | 0.050 |
Why?
|
| Hypospadias | 1 | 2005 | 80 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 1714 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 146 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 822 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 276 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1097 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 87 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 575 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2288 | 0.050 |
Why?
|
| Acute Disease | 1 | 2005 | 1184 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 494 | 0.050 |
Why?
|
| United States | 3 | 2017 | 11723 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2016 | 3131 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2008 | 893 | 0.040 |
Why?
|
| Kidney | 1 | 2008 | 1394 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2004 | 2876 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1325 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 711 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 240 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 129 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 256 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 1013 | 0.040 |
Why?
|
| Pregnancy Rate | 1 | 2000 | 40 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 13237 | 0.040 |
Why?
|
| Critical Care | 1 | 2005 | 698 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 2125 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1608 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3391 | 0.040 |
Why?
|
| Meningitis | 1 | 2018 | 101 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2018 | 97 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2018 | 95 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 1558 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2018 | 99 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 241 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 295 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5436 | 0.030 |
Why?
|
| Walking | 1 | 2018 | 233 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 196 | 0.030 |
Why?
|
| Male | 3 | 2025 | 65523 | 0.030 |
Why?
|
| Trophoblasts | 1 | 2016 | 122 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 9925 | 0.030 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 359 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 395 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 565 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 3719 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 103 | 0.030 |
Why?
|
| Vagina | 1 | 2013 | 205 | 0.020 |
Why?
|
| Chorionic Villi Sampling | 1 | 2011 | 46 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 20552 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2011 | 123 | 0.020 |
Why?
|
| Animals | 2 | 2003 | 36195 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 395 | 0.020 |
Why?
|
| Physician's Role | 1 | 2011 | 170 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2011 | 246 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 347 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 492 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1468 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1245 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 904 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2011 | 1100 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1660 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 98 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 249 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 937 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1236 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 28952 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2650 | 0.010 |
Why?
|